In Brief: Visx' Star
This article was originally published in The Gray Sheet
Visx' Star: Excimer laser is approved via PMA supplement for treatment of moderate-to-severe myopia between -6 and -12 diopters with up to -4 diopters of concomitant myopic astigmatism, the firm reports Jan. 29. The system was previously approved for myopia up to -6 diopters with myopic astigmatism of up to -4 diopters. "Greater than 99% of nearsighted consumers, with or without astigmatism, are now eligible for laser vision correction" with the device, the firm claims. The firm plans to file for approval of hyperopia treatment in the first quarter...
You may also be interested in...
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.
Operation Warp Speed chief scientific advisor confirms doubts about the Phase III data from two UK and Brazil studies; says efficacy results in US trials of AstraZeneca and Janssen vaccines expected by mid-January.